Bio-Rad Laboratories
(BIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 840,325 | 607,584 | 603,551 | 660,672 | 561,071 |
| Marketable Securities | 319,662 | 429,786 | 438,710 | 459,533 | 423,737 |
| Receivables | 402,241 | 369,767 | 380,476 | 392,672 | 356,025 |
| Inventories | 640,228 | 628,401 | 557,029 | 554,007 | 587,987 |
| Other current assets | 10,109 | 5,249 | 8,034 | 10,940 | 9,228 |
| TOTAL | $2,323,861 | $2,132,584 | $2,082,587 | $2,180,155 | $2,047,632 |
| Non-Current Assets | |||||
| PPE Net | 480,949 | 481,430 | 486,174 | 499,339 | 495,876 |
| Investments And Advances | 8,439,897 | 6,703,039 | 5,434,760 | 4,638,205 | 3,931,715 |
| Intangibles | 497,221 | 502,871 | 402,448 | 409,656 | 411,049 |
| Other Non-Current Assets | 279,003 | 277,383 | 278,389 | 281,505 | 290,844 |
| TOTAL | $9,697,070 | $7,964,723 | $6,601,771 | $5,828,705 | $5,129,484 |
| Total Assets | $12,020,930 | $10,097,310 | $8,684,359 | $8,008,859 | $7,177,116 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 426,636 | 426,502 | 426,308 | 426,172 | 1,769 |
| Accounts payable and accrued liabilities | 132,994 | 130,905 | 118,221 | 107,014 | 249,835 |
| Accrued Expenses | 190,091 | 156,388 | 130,202 | 180,084 | N/A |
| Other current liabilities | 160,903 | 147,140 | 127,785 | 86,840 | 113,490 |
| TOTAL | $986,657 | $926,895 | $869,254 | $905,495 | $434,040 |
| Non-Current Liabilities | |||||
| Long Term Debt | 12,241 | 12,233 | 12,205 | 13,579 | 437,808 |
| Deferred Revenues | N/A | N/A | N/A | 33,735 | N/A |
| Other Non-Current Liabilities | 354,229 | 348,124 | 348,709 | 336,941 | 336,075 |
| TOTAL | $2,209,129 | $1,817,010 | $1,522,026 | $1,348,307 | $1,611,884 |
| Total Liabilities | $3,195,786 | $2,743,905 | $2,391,280 | $2,253,802 | $2,045,924 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,831 | 29,678 | 29,648 | 29,925 | 29,935 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 8,428,925 | 7,123,093 | 6,156,691 | 5,470,779 | 4,917,313 |
| Other shareholders' equity | 83,904 | -61,179 | -149,357 | -87,745 | -152,556 |
| TOTAL | $8,825,145 | $7,353,402 | $6,293,079 | $5,755,057 | $5,131,192 |
| Total Liabilities And Equity | $12,020,931 | $10,097,307 | $8,684,359 | $8,008,859 | $7,177,116 |